Perrigo Company CEO On Completing The Omega Pharma Acquisition

Perrigo Company plc Ordinary Shares

recently completed its acquisition of Omega Pharma Invest N.V. Perrigo CEO Joseph Papa, was on CNBC Monday to discuss the benefits of the deal, and Perrigo's move to Ireland. The Deal "Perrigo is a company prior to Omega was competing in 7 countries, now we will be able to compete in 39 countries," Papa said. "So, it really was an opportunity for us to do a very significant European expansion and really…make us a top 5 global over the counter company. So, that's really the excitement." He continued, "We think, we can also bring all the, Perrigo today in the U.S. has about 3,000 products. We can bring many of those products to our European platform and launch them in Europe, gives us a chance to continue to have very significant revenue synergies for the future." Business Categories Papa was asked how much percentage of company's business is generic drugs. He replied, "For us its only 20 percent of our business is generic drugs. Much of what we do though is the star brand over the counter, which we put as a separate category in total will be about 70 percent over the counter about 20 percent generic prescription drugs and 10 percent will be the […] realty." Ireland Move On the company's move to Ireland, Papa said, "Well Perrigo as a company has grown, grown about mid-teens revenue growth for last 5-6 years and o has been is about half our growth organic, half of its come through M&A. If you are going to be involved in M&A, having a lower tax rates help."